Bing

SEARCH HISTORY

Investors in MannKind Corp (Symbol: MNKD) saw new options begin trading today, for the July 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the …
NASDAQ · 5/28/2015
With the stock market having finally decided to take a breather this ... with high volume and with recognized names were as follows: MannKind Corp. (NASDAQ: MNKD) in inhalable insulin; Mobileye N.V. (NYSE: MBLY) …
24/7 Wall ST · 15 hours ago
Aside from its shear velocity, the only notable thing about MNKD stock’s rally over the past two days is the distinct lack of headline news. The shares have surged nearly 16.6% since Tuesday morning, pushing the …
Investor Place · 5/28/2015
More from Bing News
... have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $6.89. MannKind (NASDAQ:MNKD) opened at 5.18 on Monday. MannKind has a 52-week low of …
Ticker Report · 20 hours ago
MNKD ) . Now that we know the company far better, it's time to ask the ultimate question: Is MannKind a buy? Ever since it went public in 2004, the stock has had both bulls and bears proclaiming the merits and …
The Motley Fool · 5/29/2015
MannKind's (NASDAQ: MNKD) inhaled insulin, Afrezza, is incredibly intriguing, but Novo Nordisk's (NYSE: NVO) long-standing dominance in diabetes treatment and its research to develop insulin in tablet form could …
Investopedia · 5/27/2015
Novo Nordisk
CHICAGO, June 1, 2015 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNKD, HZNP, ALTR, OREX and WIN. To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by …
The Business Journal · 11 hours ago
Vetr cut shares of MannKind (NASDAQ:MNKD) from a hold rating to a sell rating in a research note issued to investors on Tuesday. The firm currently has $4.69 price target on the biopharmaceutical company’s stock. MannKind (NASDAQ:MNKD) traded …
wkrb13.com · 5/28/2015
Freeport-McMoRan Inc. (FCX)’s monthly performance stand at – 3.55% with a profit margin of -20.80% and has an analyst rating of 2.4 (Click To Expand Current Stock Data:) MannKind Corp. (MNKD) of the …
wallstreetscope.com · 5/27/2015
MannKind (NASDAQ:MNKD) was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday. They currently have a $4.69 target price on the biopharmaceutical company’s stock.
Mideast Times · 5/27/2015